The European Commission approved POHERDY, making it the first and only pertuzumab biosimilar authorized in Europe. The decision is a meaningful regulatory win for Shanghai Henlius Biotech and Organon, potentially expanding access in a major market. The news is positive for both companies, though the immediate market impact is likely limited to the individual names rather than the broader sector.
The European Commission approved POHERDY, making it the first and only pertuzumab biosimilar authorized in Europe. The decision is a meaningful regulatory win for Shanghai Henlius Biotech and Organon, potentially expanding access in a major market. The news is positive for both companies, though the immediate market impact is likely limited to the individual names rather than the broader sector.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
